Serum amyloid p derivatives and their preparation and use
AssigneePromedior, Inc.
InventorsW. Scott Willett, Richard J. Caimi
Life of this patent
Estimating the term…
Abstract
One aspect of the present invention relates to the surprising discovery that modification of a glycan structure on a human SAP polypeptide can increase the biological activity of the SAP polypeptide relative to a corresponding sample of wild-type SAP isolated from human serum. The disclosure provides both variant human SAP polypeptides and methods for making the same. In particular, the present invention provides methods and compositions for in vitro and in vivo addition, deletion, or modification of sugar residues to produce SAP polypeptides, such as a human SAP polypeptide, having a desired glycosylation pattern.
Claims21
A glycosylated human Serum Amyloid P (SAP) polypeptide comprising an N-linked oligosaccharide chain, wherein at least one branch of the oligosaccharide chain terminates with a α2,3-linked sialic acid moiety.
A glycosylated human SAP polypeptide comprising an N-linked oligosaccharide chain, wherein the oligosaccharide chain has at least 50% fewer α2,6-linked sialic acid moieties than wild-type SAP isolated from human serum.
A method of making a human SAP polypeptide, comprising:
- i) expressing a human SAP polypeptide in a CHO cell;
- and
- ii) isolating the human SAP polypeptide from the cell.
A method of making an SAP polypeptide, comprising:
- i) providing an SAP polypeptide, and
- ii) enzymatically or chemically altering the SAP polypeptide to produce a glycosylated SAP polypeptide comprising an N-linked oligosaccharide.
-26. (canceled)
Dependencies are inferred from the claim text.